FDA Delays Novo's Denecimig BLA Review Over Facility Remediation

Yahoo Finance·5 Oct 2026·

·Read original

3▲0 ▼1Impact / 5

Regulation Product / Tech Pharmaceuticals

NVO ▼

Summary · why it matters

The FDA has extended its review of Novo's denecimig biologics license application for haemophilia A, citing facility remediation activities, with no new regulatory action date provided. Novo said the agency has not identified any deficiencies related to the clinical efficacy or safety data in the application. Denecimig is an investigational FVIIIa-mimetic bispecific antibody developed as a subcutaneous prophylactic treatment for adults and children with haemophilia A, including patients with inhibitors, and is being studied for once-monthly, every-two-weeks and weekly dosing. Novo submitted the BLA in September 2025 and had anticipated a decision in the third quarter of 2026; the delay stems from a pre-license inspection of the manufacturing facility and subsequent remediation requirements, which Novo said do not affect its other marketed products or its 2026 financial outlook. The company continues to target a U.S. launch of denecimig in the first half of 2027, with the submission supported by data from the FRONTIER development program, including the pivotal phase III FRONTIER2 and FRONTIER3 studies and the FRONTIER4 open-label extension.

Novo Nordisk A/S ▼